Regulatory & Legal

With OSHA standardizing on new high-accuracy tools, companies face a reckoning. Faulty air monitoring puts workers at risk, but new tech offers a defense.

A new cancer care company has tapped titans of medicine, policy, and patient advocacy to guide its mission of transforming treatment from the clinic to the home.

Olympia Pharmaceuticals unveils Circulate, a single-dose IV premix blending science and efficiency to support vascular health and streamline clinic operations.

Oakville's veteran brewery, Cameron's, makes a dual play, launching a trendy light IPA and announcing a 400-seat venue to redefine its brand.

Over 100 institutions, including BlackRock and Vanguard, now hold Chaince Digital. What's driving this quiet endorsement of a firm pivoting to AI and tokenization?

Motive's new AI automates driver records and compliance, offering a powerful shield against millions in fines and crippling administrative paperwork.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

A new partnership aims to secure the U.S. drone supply chain by manufacturing advanced, compliant battery systems for agricultural and defense applications.

New Directions Mental Health adds cutting-edge Spravato and TMS therapies, expanding access for Pennsylvanians with treatment-resistant depression.

With a clean security review, NatGold's plan to tokenize in-ground gold gains credibility, but can its ambitious vision reshape the future of money?

After facing credit downgrades and high debt, the specialty chemicals giant has struck a key deal with lenders and installed new leadership to forge a path to recovery.

Bausch + Lomb beats Q4 revenue forecasts, propelled by its blockbuster dry eye drug MIEBO, and issues a confident financial outlook for 2026.

A 106% rise in online luring and new AI tactics have experts urging parents to have safety talks with children before they ever go online.

Upwork announces a new $300M share buyback, signaling deep confidence in its AI strategy and financial health as it aims to redefine the future of work.

In a major step to prevent future health crises, the CDC has selected Cepheid to help create rapid diagnostic tests for emerging threats before they spread.

AI firm Docebo's $60M share buyback is complicated by its majority owner's surprise move and new debt, sparking questions about its strategy.

Hyliion's fuel-agnostic generator runs on diesel, meeting tough emission rules without add-ons and unlocking resilient power for defense and data centers.

Riding a wave of innovation and strategic shifts, the cruise wellness leader posts record earnings and projects over $1B in 2026 revenue.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

The produce giant reported strong 2025 earnings after divesting its vegetable unit, reducing debt, and investing in new high-growth areas like avocado oil.